Status:

COMPLETED

Study of Islet Transplantation in Type 1 Diabetic Kidney Transplant Recipients

Lead Sponsor:

Massachusetts General Hospital

Collaborating Sponsors:

Boston Area Diabetes Endocrinology Research Center (funded by NIDDK)

Conditions:

Diabetes Mellitus, Type I

Eligibility:

All Genders

18-70 years

Phase:

PHASE1

PHASE2

Brief Summary

The purpose of the study is to learn if islet transplantation is an effective treatment for Type 1 diabetes in people who have had a kidney transplant. The primary objectives of the study are: \- To...

Detailed Description

Patients will receive (an) infusion(s) of in vitro cultured islets with the goal of achieving insulin independence. For the first islet transplant, patients will receive induction therapy with rabbit ...

Eligibility Criteria

Inclusion

  • Male and female subjects
  • Age 18 to 70 years of age
  • Have insulin dependent Diabetes Mellitus Type 1
  • Are post-renal transplant on maintenance immunosuppression with stable renal function
  • HbA1c \> 7.5% or \< 7.5% and hypoglycemia unawareness

Exclusion

  • Weight more than 90 kg
  • Insulin requirement \> 60 Units/day
  • Other (non-kidney) organ transplants except prior failed pancreatic graft.
  • Untreated or unstable proliferative diabetic retinopathy
  • Presence of de novo antibody production since the renal allograft or either Class I or Class II panel-reactive anti-HLA antibodies
  • Active infection
  • Negative screen for Epstein-Barr virus (EBV)
  • Any history of malignancy except for completely resected squamous or basal cell carcinoma of the skin
  • History of Factor V Leiden mutation
  • Any coagulopathy or medical condition requiring long-term anticoagulant therapy (e.g. warfarin) after transplantation (low-dose aspirin treatment is allowed) or subjects with international normalized ratio (INR) \> 1.5
  • Severe co-existing cardiac disease
  • Persistent elevation of liver function tests at the time of study entry
  • Acute or chronic pancreatitis
  • Male subjects with elevation of prostate specific antigen
  • Pregnancy
  • Positive screen for polyoma (BK) virus
  • Untreated hyperlipidemia
  • Recent hemorrhagic stroke
  • Factors associated with an increased risk of bleeding
  • Contact PI for complete Incl-Excl criteria list.

Key Trial Info

Start Date :

May 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 1 2016

Estimated Enrollment :

7 Patients enrolled

Trial Details

Trial ID

NCT00888628

Start Date

May 1 2009

End Date

August 1 2016

Last Update

November 29 2017

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Massachusetts General Hospital

Boston, Massachusetts, United States, 02114